Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 83, Issue 1, pp 71–79 | Cite as

Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis

  • Yu Bai
  • Hai-wei Wu
  • Yan-hua ZhangEmail author
Original Article
  • 140 Downloads

Abstract

Purpose

Insufficient serum metabolite concentrations of tamoxifen can compromise treatment efficacy in patients with breast cancer. The purpose of this meta-analysis was to explore correlations between cytochrome P450 (CYP) 2D6*10 gene polymorphisms and serum concentrations of tamoxifen and its active metabolites in patients with breast cancer in Asia.

Methods

The study included a systematic literature search for cohort studies published before March 2018 in English databases (PubMed, Embase, Cochrane Library, and Web of Science) and Chinese databases (Chinese National Knowledge Infrastructure and Wan Fang database). The meta-analysis was performed using RevMan 5.3 software. Pooled means and standard deviations were calculated with 95% confidence intervals. Publication bias and sensitivity analyses were also performed using STATA 14.0.

Results

In total, 7 studies and 552 patients were included in the meta-analysis. Serum concentrations of endoxifen were significantly different in each CYP2D6*10 genotype group (p < 0.05). The CC genotype was associated with higher concentrations of 4-OH-TAM than the CT/TT genotype (p < 0.05). However, there were no statistically significant between-group differences in serum concentrations of TAM (p > 0.05). Publication bias and sensitivity analyses confirmed that the meta-analysis results were stable and reliable.

Conclusions

CYP2D6*10 polymorphisms influence the pharmacokinetics of tamoxifen in patients with breast cancer in Asia.

Keywords

Breast cancer CYP2D6*10 Pharmacokinetics Polymorphism Tamoxifen 

Notes

Acknowledgements

We would like to thank Editage (http://www.editage.com) for English language editing and publication support.

Funding

This study was supported by grants from the National Key Technologies R&D Program (no. 2016YFC0904900).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

For this type of study, a formal consent is not required. This study does not involve any human participants or animals.

Supplementary material

280_2018_3703_MOESM1_ESM.pdf (429 kb)
Supplementary material 1 (429 KB PDF)

References

  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108.  https://doi.org/10.3322/caac.21262 CrossRefGoogle Scholar
  2. 2.
    Shah R, O’Regan RM (2018) Adjuvant endocrine therapy. Cancer Treat Res 173:15–29CrossRefGoogle Scholar
  3. 3.
    Early Breast Cancer Trialists’Collaborative Group (EBCTCG) (2005) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patients-level meta-analysis of randomized trials. Lancet 378(9793):771–784CrossRefGoogle Scholar
  4. 4.
    Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE (2013) PharmGKB summary: tamoxifen pathway, pharmacokinetics. Pharmacogenet Genom 23:643–647.  https://doi.org/10.1097/FPC.0b013e3283656bc1 CrossRefGoogle Scholar
  5. 5.
    Woo HI, Lee SK, Kim J, Kim SW, Yu J, Bae SY, Lee JE, Nam SJ, Lee SY (2017) Variations in serum concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer. Oncotarget 8:100296–100311.  https://doi.org/10.18632/oncotarget.22220 Google Scholar
  6. 6.
    Thota K, Prasad K, Basaveswara Rao MV (2018) Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen Therapy. Asian Pac J Cancer Prev 19:343–350.  https://doi.org/10.22034/APJCP.2018.19.2.343 Google Scholar
  7. 7.
    de Vries Schultink AH, Zwart W, Linn SC, Beijnen JH, Huitema AD (2015) Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. Clin Pharmacokinet 54:797–810.  https://doi.org/10.1007/s40262-015-0273-3 CrossRefGoogle Scholar
  8. 8.
    Lim YC, Desta Z, Flockhart DA, Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471–478.  https://doi.org/10.1007/s00280-004-0926-7 CrossRefGoogle Scholar
  9. 9.
    Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151–159.  https://doi.org/10.1023/B:BREA.0000025406.31193.e8 CrossRefGoogle Scholar
  10. 10.
    Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AH, Pierce JP (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89(5):718–725CrossRefGoogle Scholar
  11. 11.
    Saladores P, Murdter T, Eccles D, Chowbay B, Zqheib NK, Winter S, Ganchew B, Eccles B, Gerty S, Tfayli A, Lim JS, Yap YS, Nq RC, Wong NS, Dent R, Habbal MZ, Schaeffeler E, Eichelbaum M, Schroth W, Schwab M, Brauch H (2015) Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenom J 15(1):84–94CrossRefGoogle Scholar
  12. 12.
    Schroth W, Winter S, Mürdter T, Schaeffeler E, Eccles D, Eccles B, Chowbay B, Khor CC, Tfayli A, Zgheib NK, Eichelbaum M, Schwab M, Brauch H (2017) Improved prediction of endoxifen metabolism by CYP2D6 genotype in breast cancer patients treated with tamoxifen. Front Pharmacol 8:582.  https://doi.org/10.3389/fphar.2017.00582 CrossRefGoogle Scholar
  13. 13.
    Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin Pharmacol Ther 103:770–777.  https://doi.org/10.1002/cpt.1007 CrossRefGoogle Scholar
  14. 14.
    Chin FW, Chan SC, Abdul Rahman S, Noor Akmal S, Rosli R (2016) CYP2D6 genetic polymorphisms and phenotypes in different ethnicities of malaysian breast cancer patients. Breast J 22:54–62.  https://doi.org/10.1111/tbj.12518 CrossRefGoogle Scholar
  15. 15.
    Sirachainan E, Jaruhathai S, Trachu N, Panvichian R, Sirisinha T, Ativitavas T, Ratanatharathorn V, Chamnanphon M, Sukasem C (2012) CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients. Pharmgenom Pers Med 5:149–153.  https://doi.org/10.2147/PGPM.S32160 Google Scholar
  16. 16.
    Yin SJ, Ni YB, Wang SM, Wang X, Lou YQ, Zhang GL (2012) Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. J Clin Pharm Ther 37:364–369.  https://doi.org/10.1111/j.1365-2710.2011.01298.x CrossRefGoogle Scholar
  17. 17.
    Lan B, Ma F, Zhai X, Li Q, Chen S, Wang J, Fan Y, Luo Y, Cai R, Yuan P, Zhang P, Li Q, Xu B (2018) The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. Int J Cancer.  https://doi.org/10.1002/ijc.31291 Google Scholar
  18. 18.
    Areepium N, Panomvana D, Rungwanonchai P, Sathaporn S, Voravud N (2013) Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients. Breast Cancer (Dove Med Press) 5:73–78.  https://doi.org/10.2147/BCTT.S47172 Google Scholar
  19. 19.
    Zintzaras E, Ioannidis JP (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28:123–137.  https://doi.org/10.1002/gepi.20048 CrossRefGoogle Scholar
  20. 20.
    Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13.  https://doi.org/10.1186/1471-2288-5-13 CrossRefGoogle Scholar
  21. 21.
    Harbord RM, Egger M, Sterne JA (2006) A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25:3443–3457.  https://doi.org/10.1002/sim.2380 CrossRefGoogle Scholar
  22. 22.
    Tian C, Yang Y, Li H (2014) Clinical analysis of CYP2D6 gene polymorphism with serum concentration of tamoxifen and 4-hydroxytamoxifen. Sichuan Med J 35(1):4–6Google Scholar
  23. 23.
    Xu Y, Sun Y, Yao L, Shi L, Wu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, He L, Li P, Xie Y (2008) Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 19:1423–1429.  https://doi.org/10.1093/annonc/mdn155 CrossRefGoogle Scholar
  24. 24.
    Charoenchokthavee W, Areepium N, Panomvana D, Sriuranpong V (2017) Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients. Breast Cancer (Dove Med Press) 9:249–256.  https://doi.org/10.2147/BCTT.S125745 Google Scholar
  25. 25.
    Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J (2007) Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 25:3837–3845.  https://doi.org/10.1200/JCO.2007.11.4850 CrossRefGoogle Scholar
  26. 26.
    Zhang YX, Li YF, Chen B, Zhang WX, Cai WM (2010) Correlation between polymorphisms of CYP3A5 and CYP2D6 genotypes with concentration of tamoxifen and its activity metabolism 4-hydroxytamoxifen in Chinese breast cancer patients. China Pharmacist 13(9):1229–1232Google Scholar
  27. 27.
    Lim JS, Chen XA, Singh O, Yap YS, Ng RC, Wong NS, Wong M, Lee EJ, Chowbay B (2011) Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol 71:737–750.  https://doi.org/10.1111/j.1365-2125.2011.03905.x CrossRefGoogle Scholar
  28. 28.
    Kiyotani K, Mushiroda T, Imamura CK, Tanigawara Y, Hosono N, Kubo M, Sasa M, Nakamura Y, Zembutsu H (2012) Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res Treat 131:137–145.  https://doi.org/10.1007/s10549-011-1777-7 CrossRefGoogle Scholar
  29. 29.
    Yang X, Luo B, Wu B (2013) Association between CYP2D6 polymorphism and serum concentration of endoxifen in breast cancer patients. Chin J Cancer Prev Treat 20(12):922–925Google Scholar
  30. 30.
    Lei L, Wang X, Wu XD, Wang Z, Chen ZH, Zheng YB, Wang XJ (2016) Association of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population. Am J Transl Res 8:3585–3592Google Scholar
  31. 31.
    Johnson JA, Weitzel KW (2016) Advancing pharmacogenomics as a component of precision medicine: how, where, and who? Clin Pharmacol Ther 99:154–156.  https://doi.org/10.1002/cpt.273 CrossRefGoogle Scholar
  32. 32.
    Lu J, Li H, Guo P, Shen R, Luo Y, Ge Q, Shi W, Li Y, Zhu W (2017) The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis. Onco Targets Ther 10:5429–5437.  https://doi.org/10.2147/OTT.S149197 CrossRefGoogle Scholar
  33. 33.
    Chamnanphon M, Pechatanan K, Sirachainan E, Trachu N, Chantratita W, Pasomsub E, Noonpakdee W, Sensorn I, Sukasem C (2013) Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen therapy. Pharmgenom Pers Med 6:37–47Google Scholar
  34. 34.
    Kiyotani K, Mushiroda T, Sasa M (2008) Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 99(5):995–999CrossRefGoogle Scholar
  35. 35.
    Helland T, Henne N, Bifulco E, Naume B, Borgen E, Kristensen VN, kvaløy JT, Lash TL, Alnæs GIG, van Schaik RH, Janssen EAM, Hustad S, Lien EA, Mellgren G, Søiland H (2017) Serum concentration of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Breast Cancer Res 19(1):125CrossRefGoogle Scholar
  36. 36.
    Chau SB, Thomas RE (2015) The AmpliChip: a review of its analytic and clinical validity and clinical utility. Curr Drug Saf 10:113–124CrossRefGoogle Scholar
  37. 37.
    de Leon J, Susce MT, Murray-Carmichael E (2006) The AmpliChip CYP450 genotyping test: Integrating a new clinical tool. Mol Diagn Ther 10:135–151CrossRefGoogle Scholar
  38. 38.
    Neven P, Jongen L, Lintermans A, Van AK, Blomme C, Lambrechts D, Poppe A, Wildiers H, Dieudomne AS, Brouckaert O, Decloedt J, Berteloot P, Verhoeven D, Joerger M, Vuylsteke P, Wynendaele W, Casteels M, Van HS, Lybaert W, Van GJ, Paridaens R, Vergote I, Dezentje VO, Van CB, Guchelaar HJ (2018) Tamoxifen metabolism and efficacy in breast cancer: a prospective multicenter trial. Clin Cancer Res 24(10):2312–2318CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of PharmacyPeking University Cancer Hospital and InstituteBeijingPeople’s Republic of China

Personalised recommendations